Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...

Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your search ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00. In the following chart, we are able to follow the development of ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8522 ...

Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also the company’s first commercial product—has notably struggled to ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 vaccine sales.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...

A year earlier, Moderna earned $217 million, or 55 cents a share. The company's fourth-quarter sales slid 65% to $966 million, above analysts’ expectations.. Shares rose almost 3% Friday afternoon.

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...